Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Ohm Laboratories, Inc.
WARNING LETTER
•Ohm Laboratories, Inc.•August 12, 2009

Ohm Laboratories, Inc. – FDA Warning Letter, Aug 12, 2009

Record Details

The FDA issued a Warning Letter to Ohm Laboratories, Inc. following a July-August 2009 inspection, citing significant Current Good Manufacturing Practice (CGMP) violations (21 CFR Parts 210 and 211). These deficiencies render their drug products adulterated under Section 501(a)(2)(B) of the Act. Key CGMP issues included inadequate investigations into batch failures and OOS results (21 CFR § 211.192), failure to comply with and establish an adequate stability program (21 CFR § 211.166), and insufficient laboratory control mechanisms and documentation (21 CFR § 211.160(a)). The firm also lacked scientifically sound specifications (21 CFR § 211.160(b)), appropriate computer system controls (21 CFR § 211.68(b)), written process validation procedures (21 CFR § 211.110(a)), adequate qualified personnel (21 CFR § 211.25(c)), and equipment calibration (21 CFR § 211.68(a)). Additionally, Post Marketing Violations included failing to report distributed drug quantities in annual reports (21 CFR § 314.81(b)(2)(ii)) and not submitting timely NDA-Field Alert Reports (21 CFR § 314.81(b)(1)(ii)). The firm was also manufacturing and distributing an unapproved new prescription drug, violating sections 301(d) and 505(a) of the Act. The firm's initial response was deemed insufficient. Prompt corrective actions are required within fifteen working days to prevent legal action, including seizure and injunction, and potential impact on approvals. The FDA highlighted similar violations at other Ranbaxy facilities, urging a comprehensive global assessment.

Company
Ohm Laboratories, Inc.
Inspection date
August 12, 2009
Product type
Drugs
Office
New York District Office
Person
  • Laurence Daurio
View Company Profile

ID · f6bd8d6f-d576-4d1a-a120-d64d77f7234f

Violation Codes10
21 CFR 21021 CFR 21121 U.S.C. 331(d)21.U.S.C. 355(a)21 CFR 314.81(b)(2)(ii)21 CFR 314.81(b)(1)(ii)21 CFR 211.19221 CFR 211.19821 CFR 211.166(a)21 CFR 211.166(b)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Ohm Laboratories, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.